National Academies Press: OpenBook
« Previous: 10 Improving the Quality of Research on the Long-Term Health Effects of Antimalarial Drugs
Suggested Citation:"Appendix A: Public Meeting Agendas." National Academies of Sciences, Engineering, and Medicine. 2020. Assessment of Long-Term Health Effects of Antimalarial Drugs When Used for Prophylaxis. Washington, DC: The National Academies Press. doi: 10.17226/25688.
×

Appendix A

Public Meeting Agendas

FIRST PUBLIC MEETING

January 28, 2019
National Academy of Sciences Building
2101 Constitution Avenue, NW
Washington, DC 20001
Board Room

1:00–1:10 p.m. ET Welcome and introductions; Conduct of the Open Session
David Savitz, Ph.D., Committee Chair
1:10–1:50 p.m. Charge to the Committee
Peter R. Rumm, M.D., M.P.H., Director, Pre-9/11 Era Environmental Health Program, Department of Veterans Affairs, with Dr. R. Loren Erickson, Chief Consultant, Post Deployment Health
1:50–2:20 p.m. Overview of Antimalarials Use Policy and Monitoring in Service Members
COL Andrew Wiesen, M.D., M.P.H., Director, Preventive Medicine, Health Readiness Policy and Oversight, Office of the Assistant Secretary of Defense (Health Affairs)
Suggested Citation:"Appendix A: Public Meeting Agendas." National Academies of Sciences, Engineering, and Medicine. 2020. Assessment of Long-Term Health Effects of Antimalarial Drugs When Used for Prophylaxis. Washington, DC: The National Academies Press. doi: 10.17226/25688.
×
2:20–2:50 p.m. Food and Drug Administration Adverse Events Reporting System
Kelly Yoojung Cao, Pharm.D., Team Leader, Division of Pharmacovigilance II, Food and Drug Administration
2:50–3:30 p.m. Centers for Disease Control and Prevention Monitoring of Malaria and Research Related to Antimalarials Use
Kathrine Tan, M.D., M.P.H., Chief, Domestic Response Unit, Malaria Branch, Centers for Disease Control and Prevention
3:30–3:50 p.m. Identifying and Evaluating Sources of Evidence of Quinism: A Novel Disease Affecting U.S. Veterans
Remington Nevin, M.D., M.P.H., Dr.P.H., Executive Director, The Quinism Foundation
3:50–4:20 p.m.1 Public Comments
Limited to 3 minutes per individual/organization
4:20 p.m. OPEN SESSION ENDS

_______________

1 To be extended if needed to accommodate those wishing to make a public statement.

Suggested Citation:"Appendix A: Public Meeting Agendas." National Academies of Sciences, Engineering, and Medicine. 2020. Assessment of Long-Term Health Effects of Antimalarial Drugs When Used for Prophylaxis. Washington, DC: The National Academies Press. doi: 10.17226/25688.
×

SECOND PUBLIC MEETING AGENDA

March 27, 2019
OPEN SESSION
Keck Building
500 Fifth Street, NW, Washington, DC
Keck Room 105

9:30–9:35 a.m. ET Welcome and Introductions; Conduct of the Open Session
David Savitz, Ph.D., Committee Chair
9:35–10:05 a.m. Overview of Antimalarials Use Policy and Monitoring in Peace Corps Volunteers
Kyle Petersen, D.O, F.I.D.S.A., F.A.C.P., Director of Epidemiology, Peace Corps
10:05–10:25 a.m. Antimalarials—Use Policy and Monitoring in Deployed Employees of Department of State
Kim Ottwell, M.D., Clinical Director of Clinical Services
10:25–11:25 a.m. Neurotoxic Mechanisms of Antimalarials
Thomas Brewer, M.D., University of Washington, and Principle, Global Enterics, LLC
11:25–11:50 a.m. Public Comments
Limited to 3 minutes per individual/organization
11:50 a.m. OPEN SESSION ENDS
Suggested Citation:"Appendix A: Public Meeting Agendas." National Academies of Sciences, Engineering, and Medicine. 2020. Assessment of Long-Term Health Effects of Antimalarial Drugs When Used for Prophylaxis. Washington, DC: The National Academies Press. doi: 10.17226/25688.
×

This page intentionally left blank.

Suggested Citation:"Appendix A: Public Meeting Agendas." National Academies of Sciences, Engineering, and Medicine. 2020. Assessment of Long-Term Health Effects of Antimalarial Drugs When Used for Prophylaxis. Washington, DC: The National Academies Press. doi: 10.17226/25688.
×
Page 379
Suggested Citation:"Appendix A: Public Meeting Agendas." National Academies of Sciences, Engineering, and Medicine. 2020. Assessment of Long-Term Health Effects of Antimalarial Drugs When Used for Prophylaxis. Washington, DC: The National Academies Press. doi: 10.17226/25688.
×
Page 380
Suggested Citation:"Appendix A: Public Meeting Agendas." National Academies of Sciences, Engineering, and Medicine. 2020. Assessment of Long-Term Health Effects of Antimalarial Drugs When Used for Prophylaxis. Washington, DC: The National Academies Press. doi: 10.17226/25688.
×
Page 381
Suggested Citation:"Appendix A: Public Meeting Agendas." National Academies of Sciences, Engineering, and Medicine. 2020. Assessment of Long-Term Health Effects of Antimalarial Drugs When Used for Prophylaxis. Washington, DC: The National Academies Press. doi: 10.17226/25688.
×
Page 382
Next: Appendix B: Invited Presentations »
Assessment of Long-Term Health Effects of Antimalarial Drugs When Used for Prophylaxis Get This Book
×
Buy Paperback | $90.00 Buy Ebook | $69.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

Among the many who serve in the United States Armed Forces and who are deployed to distant locations around the world, myriad health threats are encountered. In addition to those associated with the disruption of their home life and potential for combat, they may face distinctive disease threats that are specific to the locations to which they are deployed. U.S. forces have been deployed many times over the years to areas in which malaria is endemic, including in parts of Afghanistan and Iraq. Department of Defense (DoD) policy requires that antimalarial drugs be issued and regimens adhered to for deployments to malaria-endemic areas. Policies directing which should be used as first and as second-line agents have evolved over time based on new data regarding adverse events or precautions for specific underlying health conditions, areas of deployment, and other operational factors

At the request of the Veterans Administration, Assessment of Long-Term Health Effects of Antimalarial Drugs When Used for Prophylaxis assesses the scientific evidence regarding the potential for long-term health effects resulting from the use of antimalarial drugs that were approved by FDA or used by U.S. service members for malaria prophylaxis, with a focus on mefloquine, tafenoquine, and other antimalarial drugs that have been used by DoD in the past 25 years. This report offers conclusions based on available evidence regarding associations of persistent or latent adverse events.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!